Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies.

Meinke S, Sandgren P, Mörtberg A, Karlström C, Kadri N, Wikman A, Höglund P.

Transfusion. 2016 Feb;56(2):370-82; quiz 369. doi: 10.1111/trf.13350. Epub 2015 Oct 7.

PMID:
26442787
2.

Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.

Figueiredo C, Blaszczyk R.

J Stem Cells. 2014;9(3):149-61. doi: jsc.2014.9.3.149. Review.

PMID:
25157449
3.

HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.

Gras C, Schulze K, Goudeva L, Guzman CA, Blasczyk R, Figueiredo C.

Hum Gene Ther. 2013 Dec;24(12):1018-28. doi: 10.1089/hum.2013.074. Epub 2013 Nov 7.

PMID:
24090417
5.

In vitro testing of fresh and lyophilized reconstituted human and baboon platelets.

Valeri CR, Macgregor H, Barnard MR, Summaria L, Michelson AD, Ragno G.

Transfusion. 2004 Oct;44(10):1505-12.

PMID:
15383025
6.

Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review.

Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, Shehata N; International Collaboration for Guideline Development, Implementation and Evaluation for Transfusion Therapies (ICTMG) Collaborators.

Transfusion. 2013 Oct;53(10):2230-42. doi: 10.1111/trf.12175. Epub 2013 Apr 3. Review.

PMID:
23550773
7.

Recovery, survival, and function of transfused platelets and detection of platelet engraftment after allogeneic stem cell transplantation.

Vetlesen A, Holme PA, Lyberg T, Kjeldsen-Kragh J.

Transfusion. 2012 Jun;52(6):1321-32. doi: 10.1111/j.1537-2995.2011.03442.x. Epub 2011 Nov 16.

PMID:
22084943
8.

Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation.

Lucas G, Culliford S, Green F, Sidra G, Calvert A, Green A, Harrison P, Harvey J, Allen D, Smillie D, Masurekar A, Marks D, Russell N, Massey E.

Transfusion. 2010 Feb;50(2):334-9. doi: 10.1111/j.1537-2995.2009.02448.x. Epub 2009 Oct 23.

PMID:
19874563
9.

Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients.

Fontaine MJ, Kuo J, Chen G, Galel SA, Miller E, Sequeira F, Viele M, Goodnough LT, Tyan DB.

Transfusion. 2011 Dec;51(12):2611-8. doi: 10.1111/j.1537-2995.2011.03194.x. Epub 2011 May 26.

PMID:
21615749
10.

Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies.

Gerber B, Alberio L, Rochat S, Stenner F, Manz MG, Buser A, Schanz U, Stussi G.

Transfusion. 2016 Oct;56(10):2426-2437. doi: 10.1111/trf.13690. Epub 2016 Jun 24.

PMID:
27339466
11.

Effects of pretransfusion warming of platelets to 35 degrees C on posttransfusion platelet viability.

Slichter SJ, Christoffel T, Corson J, Jones MK, Pellham E, Bolgiano D.

Transfusion. 2009 Nov;49(11):2319-25. doi: 10.1111/j.1537-2995.2009.02313.x. Epub 2009 Jul 16.

PMID:
19624609
12.

Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions.

Börger AK, Eicke D, Wolf C, Gras C, Aufderbeck S, Schulze K, Engels L, Eiz-Vesper B, Schambach A, Guzman CA, Lachmann N, Moritz T, Martin U, Blasczyk R, Figueiredo C.

Mol Med. 2016 Sep;22:274-285. doi: 10.2119/molmed.2015.00235. Epub 2016 May 16.

13.

Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets.

Charania R, Smith J, Vesely SK, Dale GL, Holter J.

Transfusion. 2011 Dec;51(12):2690-4. doi: 10.1111/j.1537-2995.2011.03179.x. Epub 2011 Jun 3.

PMID:
21645004
14.

Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.

Waterman HR, Kapp LM, Munday A, Odem-Davis K, Zimring JC.

Transfusion. 2016 Jan;56(1):91-100. doi: 10.1111/trf.13270. Epub 2015 Sep 24.

PMID:
26400622
15.

Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).

Wiita AP, Nambiar A.

Transfusion. 2012 Oct;52(10):2146-54. doi: 10.1111/j.1537-2995.2012.03593.x. Epub 2012 Mar 12.

PMID:
23113654
16.

Pressure-aided transfusion of platelets: does it affect the platelets?

Fischer-Nielsen A, Stissing T, Maansson C, Joergensen BG.

Transfusion. 2010 Feb;50(2):361-5. doi: 10.1111/j.1537-2995.2009.02396.x. Epub 2009 Sep 24.

PMID:
19788509
17.

Posttransfusion platelet increments after different platelet products in neonates: a retrospective cohort study.

Honohan A, van't Ende E, Hulzebos C, Lopriore E, van't Verlaat E, Govaert P, Brand A, van der Bom J.

Transfusion. 2013 Dec;53(12):3100-9. doi: 10.1111/trf.12127. Epub 2013 Feb 26.

PMID:
23441721
18.

Apheresis donors and platelet function: inherent platelet responsiveness influences platelet quality.

Garner SF, Jones CI, Stephens J, Burns P, Walton J, Bernard A, Angenent W, Ouwehand WH, Goodall AH; BLOODOMICS Consortium.

Transfusion. 2008 Apr;48(4):673-80. doi: 10.1111/j.1537-2995.2007.01591.x. Epub 2008 Jan 10.

PMID:
18194381
19.

C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.

Jackman RP, Lee JH, Pei R, Bolgiano D, Lebedeva M, Slichter SJ, Norris PJ.

Transfusion. 2016 Jun;56(6):1442-50. doi: 10.1111/trf.13598. Epub 2016 Apr 15.

20.

Supplemental Content

Support Center